Small Molecule Inhibitors as an Alternative to Antibody Blockade in Immunotherapy
Received Date: Oct 26, 2019 / Accepted Date: Nov 11, 2019 / Published Date: Nov 18, 2019
Abstract
The application of immune checkpoint blockade for the treatment of cancer has revolutionized immunotherapy regimes over the past few years. This approach has seen much success using antibody blockade of programmed cell death-1 (PD-1) or its ligand, PD-L1. However, there are many limitations to antibody blockade, including cost, tumour penetration and autoimmune complications. Patients may suffer from adverse side effects and many remain uncured. Combination of therapies with antibodies can improve response rates, but may also increase serious side effects. Here, we look at the use of small molecule inhibitors as an alternative to antibodies in targeting intracellular pathways for co-receptor blockade and synergies in immunotherapy.
Keywords: Immunology; T-Lymphocyte; Immunotherapy; Antibody
Citation: Rudd CE , Taylor A (2019) Small Molecule Inhibitors as an Alternative to Antibody Blockade in Immunotherapy. J Mucosal Immunol Res 3: 114.
Copyright: © 2019 Rudd CE, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
51ºÚÁϳԹÏÍø Journals
Article Usage
- Total views: 2342
- [From(publication date): 0-2019 - Jun 25, 2025]
- Breakdown by view type
- HTML page views: 1554
- PDF downloads: 788
